Beta Bionics (NASDAQ:BBNX) Upgraded at Wells Fargo & Company

Beta Bionics (NASDAQ:BBNX) was upgraded by research analysts at Wells Fargo & Company to a “strong-buy” rating in a note issued to investors on Wednesday, Zacks reports.

A number of other equities analysts have also weighed in on the company. Leerink Partners increased their price target on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, September 14th. Bank of America upped their price objective on shares of Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. UBS Group reiterated a “buy” rating and issued a $25.00 target price on shares of Beta Bionics in a report on Tuesday, September 15th. William Blair began coverage on shares of Beta Bionics in a research note on Friday, August 21st. They issued a “market perform” rating for the company. Finally, Wall Street Zen raised Beta Bionics from a “sell” rating to a “hold” rating in a research report on Saturday, September 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Beta Bionics presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.45.

Beta Bionics Trading Down 2.7%

Shares of Beta Bionics stock opened at $22.19 on Wednesday. Beta Bionics has a 52 week low of $8.80 and a 52 week high of $32.71. The company’s 50-day moving average price is $17.98 and its two-hundred day moving average price is $14.29. The stock has a market cap of $998.33 million, a PE ratio of -13.45 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, equities analysts predict that Beta Bionics will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, insider Mark Hopman sold 30,779 shares of Beta Bionics stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total transaction of $619,581.27. Following the sale, the insider directly owned 56,479 shares of the company’s stock, valued at approximately $1,136,922.27. The trade was a 35.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mike Mensinger sold 2,650 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total value of $58,300.00. Following the completion of the transaction, the insider directly owned 177,390 shares of the company’s stock, valued at approximately $3,902,580. The trade was a 1.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 107,327 shares of company stock worth $2,070,421 in the last 90 days. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Beta Bionics

A number of large investors have recently bought and sold shares of BBNX. Squarepoint Ops LLC bought a new position in shares of Beta Bionics during the second quarter valued at $2,524,000. Bank of America Corp DE acquired a new stake in shares of Beta Bionics during the 2nd quarter worth about $8,566,000. Man Group plc bought a new position in Beta Bionics during the 2nd quarter valued at about $419,000. Legal & General Group Plc acquired a new position in Beta Bionics in the second quarter valued at about $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Beta Bionics during the second quarter worth approximately $172,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics announced a partnership with Senseonics to integrate its iLet Bionic Pancreas and mint automated insulin-delivery systems with Senseonics’ Eversense 365 continuous glucose monitor. The combined iLet-Eversense system is expected to launch commercially in the fourth quarter of 2026, potentially expanding customer choice and strengthening BBNX’s competitive position in automated diabetes management. Beta Bionics Announces Agreement to Integrate Its Systems with Senseonics’ Eversense 365
• Neutral Sentiment: Multiple law firms publicized the same pending securities class action against Beta Bionics. The proposed class covers investors who purchased shares from July 30, 2025, through February 24, 2026, with November 3, 2026, set as the lead-plaintiff deadline. The notices themselves largely repeat existing litigation information, but they increase visibility around the claims and potential legal costs. BBNX Investor Deadline and Class Action Notice
• Negative Sentiment: The lawsuit alleges Beta Bionics failed to disclose or adequately describe FDA concerns, including a June 2025 Form 483 and more than 18,000 iLet complaints. The allegations claim subsequent disclosures about the FDA’s concerns and medical-device safety led to a sharp decline in BBNX shares. These claims have not been proven, but the litigation creates regulatory, reputational and financial uncertainty. Johnson Fistel BBNX Investor Alert
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her holdings by about 24.7%. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, which somewhat limits its value as a discretionary bearish signal; however, it adds to reported insider-selling activity and there have been no recent open-market insider purchases highlighted in the coverage. SEC Form 4 Filing

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.